|Awarded On||August 21, 2019|
|Title||Targeting ARNT and RBFOX2 alternative splicing as a novel treatment modality in lymphoid malignancies|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Casey W Wright|
|Cancer Sites||Leukemia, Lymphoma|
*Pending contract negotiation
Non-Hodgkin lymphoma (NHL) includes a number of aggressive T and B cell lymphomas that predominantly affect children. For example, anaplastic large cell lymphoma is a peripheral T-NHL that constitutes 40% of NHL in children. Similarly, Burkitt lymphoma, a B-NHL, accounts for 30% of all childhood lymphoma. Most patients respond well to treatment using standard chemotherapy. However, a majority often relapse and require more intense therapy, putting these patients in jeopardy for developing toxic side effects should the cancer go back into remission. This project aims to test the efficacy of novel splice-switching oligonucleotides in blocking the pro-cancerous functions of specific genes in ly...